Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico

Archives of Internal Medicine

Volumn 160, Issue 5, 2000, Pages 630-636

  García García, Maria De Lourdes ^a   Ponce De León, Alfredo ^c   Jiménez Corona, Maria Eugenia ^a   Jiménez Corona, Aída ^a   Palacios Martínez, Manuel ^a   Balandrano Campos, Susana ^d   Ferreyra Reyes, Leticia ^a   Juárez Sandino, Luis ^a   Sifuentes Osornio, José ^c   Olivera Díaz, Hiram ^d   Valdespino Gómez, José Luis ^a   Small, Peter M ^b  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b STANFORD UNIVERSITY   (United States)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d Instituto Nacional de Diagnostico y Referencia Epidemiologicos   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ACID FAST BACTERIUM; ADULT; ARTICLE; BACTERIUM ISOLATION; DEVELOPING COUNTRY; DISEASE TRANSMISSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETREATMENT; SPUTUM SMEAR; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0242608155     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.5.630     Document Type: Article

References (26)

1. Kochi A. Tuberculosis control: is DOTS the health breakthrough of the 1990s? World Health Forum. 1997;18:225-232.
2. Pablos-Mendez A, Raviglione MC, Laszlo A, et al, for the World Health Organization -International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. Global surveillance for antituberculosis-drug resistance, 1994-1997 [published correction appears in N Engl J Med. 1998;339:139]. N Engl J Med. 1998;338:1641-1649.
3. Pablos-Mendez A, Raviglione MC, Laszlo A, et al, for the World Health Organization - International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. Global surveillance for antituberculosis-drug resistance, 1994-1997 [published correction appears in N Engl J Med. 1998;339:139]. N Engl J Med. 1998;338:1641-1649.
4. Garcia-Garcia ML, Small PM, Garcia SC, et al. Tuberculosis epidemiology and control in Veracruz, Mexico, Int J Epidemiol. 1999;28:135-140.
5. Garcia-Garcia ML, Palacios Martinez M, Ponce-de-León A, et al. The role of core groups in transmitting M tuberculosis in a high prevalence community in Southern Mexico, Int J Tuberc Lung Dis. 1999;4:1-6.
6. Secretaria de Salud, Norma oficial para el control y prevención de la tuberculosis en la atención primaria a la salud. Diario Oficial. 1995;496:20-29. Norma No. NOM-006-SSAA2-1993.
7. Nolte FS, Mechock B, Mycobacterium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 6th ed. Washington, DC: ASM Press; 1995:400-437.
8. van Embden JDA, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993;31:406-409.
9. Woeltfer BF, Bradford WZ, Paz A, Small PM. A computer assisted molecular epidemiologic approach for confronting the re-emergence of tuberculosis. Am J Med Sci. 1995;311:17-22.
10. Instituto Nacional de Estadistica, Geografia, e Informatica. Anuario Estadistico del Estado de Veracruz, Mexico. Aguascalientes, Mexico: Talleres Graficos del Instituto Nacional de Estadistica, Geografia, e Informatica; 1995:125-446.
11. Kin SJ, Bai GH, Hong YP. Drug resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis. 1997;1:302-308.
12. Styblo K, Dankova D, Drapela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia: report for the first four years of the study (1961-1964). Bull World Health Organ. 1967;37:819-874.
13. Boulahbal F, Knaled S, Tazir M. The interest of follow-up of resistance of the tubercle bacillus in the evaluation of a programme. Bull Int Union Tuberc Lung Dis. September 1989;64:23-25.
14. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945-951.
15. Fujiwara PI, Larkin C, Frieden TR. Directly observed therapy in New York City: history, implementation, results, and challenges. Clin Chest Med. 1997;18:135-148.
16. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994; 330:1179-1184.
17. Chaulet P, Zidouni N. Evaluation of applied strategies of tuberculosis control in the developing world. In: Reichman L, Hershfield E, eds. Tuberculosis. New York, NY: Marcel Dekker Inc; 1992;601-627.
18. Lazslo A, De Kantor IN. A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ. 1994;72:603-610.
19. Centers tor Disease Control and Prevention. Population-based survey for drug resistance of tuberculosis - Mexico, 1997. MMWR Morb Mortal Wkly Rep. 1998; 47:371-375.
20. Sifuentes-Osornio J, Ponce-de-León A, Bobadilla-del-Valle M, et al. Drug resistance in Mycobacterium tuberculosis: a survey in the central area of Mexico [abstract], Clin Infect Dis. 1996;23:886.
21. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from AFB smear-negative patients. Lancet. 1999;353:444-449.
22. Kato-Maeda M, Sifuentes-Osornio J, Bobadilla del Valle M, Ruiz-Palacios GM, Ponce-de-León A. Drug resistance among acid-fast bacilli smear negative tuberculosis patients in the Sierra Madre of Mexico [letter]. Lancet. 1999;353: 1709.
23. Cohn ML, Kovitz C, Oda U, Middlebrook G. Studies on isoniazid and tubercle bacilli: the growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. Am Rev Tuberc. 1954;70:641-664.
24. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis. 1985;132:125-132.
25. Park MM, Davis AL, Schlunger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1991: prolonged survival with appropriate therapy. Am J Respir Crit Care Med. 1996;153:317-324.
26. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rilampin. Int J Tuberc Lung Dis. 1998;2:877-884.